Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The potential of these natural hemp-derived compounds is amazing, posters that claim otherwise are spreading FUD
The pain-killing effects are in part due to desentization of TRP channels (pain-sensing receptors) see below
BACKGROUND AND PURPOSE
Cannabidiol (CBD) and D9-tetrahydrocannabinol (THC) interact with transient receptor potential (TRP) channels and enzymes
of the endocannabinoid system.
EXPERIMENTAL APPROACH
The effects of 11 pure cannabinoids and botanical extracts [botanical drug substance (BDS)] from Cannabis varieties selected
to contain a more abundant cannabinoid, on TRPV1, TRPV2, TRPM8, TRPA1, human recombinant diacylglycerol lipase a
(DAGLa), rat brain fatty acid amide hydrolase (FAAH), COS cell monoacylglycerol lipase (MAGL), human recombinant
N-acylethanolamine acid amide hydrolase (NAAA) and anandamide cellular uptake (ACU) by RBL-2H3 cells, were studied
using fluorescence-based calcium assays in transfected cells and radiolabelled substrate-based enzymatic assays. Cannabinol
(CBN), cannabichromene (CBC), the acids (CBDA, CBGA, THCA) and propyl homologues (CBDV, CBGV, THCV) of CBD,
cannabigerol (CBG) and THC, and tetrahydrocannabivarin acid (THCVA) were also tested.
KEY RESULTS
CBD, CBG, CBGV and THCV stimulated and desensitized human TRPV1. CBC, CBD and CBN were potent rat TRPA1 agonists
and desensitizers, but THCV-BDS was the most potent compound at this target. CBG-BDS and THCV-BDS were the most
potent rat TRPM8 antagonists. All non-acid cannabinoids, except CBC and CBN, potently activated and desensitized rat
TRPV2. CBDV and all the acids inhibited DAGLa. Some BDS, but not the pure compounds, inhibited MAGL. CBD was the
only compound to inhibit FAAH, whereas the BDS of CBC > CBG > CBGV inhibited NAAA. CBC = CBG > CBD inhibited ACU,
as did the BDS of THCVA, CBGV, CBDA and THCA, but the latter extracts were more potent inhibitors.
CONCLUSIONS AND IMPLICATIONS
These results are relevant to the analgesic, anti-inflammatory and anti-cancer effects of cannabinoids and Cannabis extracts
Clinical trials are underway to evaluate efficacy of the CBD family of compounds in humans. See one below.
Diabetes Care. 2016 Oct;39(10):1777-86. doi: 10.2337/dc16-0650. Epub 2016 Aug 29.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
\
Cannabidiol (CBD) and ?(9)-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS:
In this randomized, double-blind, placebo-controlled study, 62 subjects with noninsulin-treated type 2 diabetes were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks. The primary end point was a change in HDL-cholesterol concentrations from baseline. Secondary/tertiary end points included changes in glycemic control, lipid profile, insulin sensitivity, body weight, liver triglyceride content, adipose tissue distribution, appetite, markers of inflammation, markers of vascular function, gut hormones, circulating endocannabinoids, and adipokine concentrations. Safety and tolerability end points were also evaluated.
RESULTS:
Compared with placebo, THCV significantly decreased fasting plasma glucose (estimated treatment difference [ETD] = -1.2 mmol/L; P < 0.05) and improved pancreatic ß-cell function (HOMA2 ß-cell function [ETD = -44.51 points; P < 0.01]), adiponectin (ETD = -5.9 × 10(6) pg/mL; P < 0.01), and apolipoprotein A (ETD = -6.02 µmol/L; P < 0.05), although plasma HDL was unaffected. Compared with baseline (but not placebo), CBD decreased resistin (-898 pg/ml; P < 0.05) and increased glucose-dependent insulinotropic peptide (21.9 pg/ml; P < 0.05). None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated.
CONCLUSIONS:
THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.
I agree with you Bruschisheart, it's all about sales growth and execution of the management, and POTN has it all.
Experience with Diamond Relax gummies:
If you work full time you might want to try one on a Friday night, it was very potent for me. The relaxation effect lasted 2 days, I slept a solid 9 hours for 2 nights in a row after one piece.
I have remained invested in this stock for the last year or more waiting for the ZTE license announcement that Merritt said was well under way through negotiation. Has there been any mention of this? I saw posts a few months ago about a court date.
Thanks
I also have the CBD gummies which say 30mg on the package (haven't tried them yet). I couldn't find the dose on Relax gummies, but I think they are stronger. I think a lighter dose would be ok for me, right now I am not under alot of stress. And i agree with the others, they taste great.
I ordered Relax gummies and was impressed with the quality of the web site, ease of ordering and amount of email notifications about the fast, free shipping. I tried one gummy after work yesterday. Within an hour I felt more relaxed, a little sleepy and I would say that the pain from the crick in my neck was about half or less. I slept more deeply that I have for ages. Usually I take a benedryl to help if I am having trouble sleeping but quit using it when reports cam out that long-term use significantly effects memory.
Does anybody know which is stronger, Relax or Chill gummies? Web site was out of chill gummies a few weeks ago. For me, at weight 130, one Relax gummy was plenty potent.
Amazon does not sell anything like this. Another lie.
I am very pleased to see that Diamond is using curcumin/turmeric in their new product line. I take a turmeric capsule every day- it is a miracle therapeutic for inflammation with the side effect of potent anti-cancer activity. If you have arthritis, diabetes, cancer, gout, dementia/ alzheimer's or any other inflammatory disease you should be taking it. Word is getting out about natural compounds to treat illnesses.
I have known a number of professional adults that smoke weed to sleep. This is a better alternative if you are on vacation, have kids, etc...
I am very excited to see today's news. I am a pharma research scientist working at an academic basic science and clinical research institution. My lab studies effects of herbal and food derived natural compounds on weight loss and diabetes. These compounds, like those in hemp, have been used as medicines for thousands of years by ancient cultures (China, India, Africa) and they have real efficacy without side effects. This is the tip of the iceberg- we are working to educate US physicians about these alternative therapies. When I think of the market just for insomnia and anxiety alone it is mind blowing. I got into POTN in Dec and am holding all of my shares until at least $10. Looks like management is doing great things.
Strange price action today, especially considering this stock got a lot less risky yesterday with the release of January numbers. I wonder who was buying all the way to .95 last month?
I grabbed some at .544 this morning, I was surprised anyone was selling today!
I agree. $1.25 after January earnings, $3 by end of 2018. You may not get any below .5 after this week.
He is a great contrarian indicator- we are going up today.
That answered my question, it takes a long time to be approved after uplist application. Probably not happening this month.
I have a VERY good feeling about Jan earnings. It occurred to me that the Co is waiting for the uplist approval to release the news with the audit- can getting approval for that happen quickly if the audit looks good?
This made the national TV news this morning
https://www.texastribune.org/2018/02/01/six-year-old-texan-first-state-receive-medical-cannabis-oil/
A six-year-old Texan on Thursday became the first person in the state to receive a legal delivery of medical cannabis — more than two years after Republican Gov. Greg Abbott signed a law legalizing the sale of a specific kind of cannabis oil to Texans with intractable epilepsy.
BY ALEX SAMUELS FEB. 1, 2018 1 PM
Anybody have an idea when we get the preliminary sales numbers for January? It would be nice to see them come out with the audit for 2017 in the next few weeks.
Anybody have an idea when we get the preliminary sales numbers for January? It would be nice to see them come out with the audit for 2017 in the next few weeks.
I manage a preclinical research lab and we study botanical compounds and natural extracts that treat diabetes and stimulate weight loss- they have very robust effects. I bought my first shares of POTN in Dec at 0.06 and since then, I have been researching the CBD family of compounds for their cellular mechanisms and therapeutic potential. IMO, the potential is unlimited if the POTN management is capable. These CBD compounds lower anxiety, desensitize pain, and lower appetite with no side effects. If you consider the market for treating these problems and insomnia, it is very exciting. Once POTN is included in an ETF like HMMJ, this stock will roar even higher in the future. I bought more today and plan to hold for at least a year. Looking for $10 or higher.
Hey la or others that have done DD on this stock for a while- know anything about management? Are they capable of guiding this company 10-fold higher to a billion $ market cap?
Appreciate your analyses ClayTrader, please keep them coming. I buy and hold and stay in as long as management is executing well and catalysts are upcoming, but I like to know where danger levels are at the bottom and resistance levels are at the top.
Clay Trader knows charts, glad we held .40, we should move back up from here after some consolidation. Just think about the share price when POTN is held by ETFs like HMMJ, sky is the limit!
This is a great buying opportunity- I know, I am having trouble getting orders filled.
In a phone conversation I just asked a mutual fund/retirement advisor at Charles Schwab if he followed pot stocks and he said he was watching a few. When I asked specifically about POTN, he sounded excited and said it was a popular private investment among several of his colleagues.
Sure hope it's ZTE! Volume is unusually high.
Based on my many years of being invested, IDCC always comes through when things seem the lowest. I am hanging on waiting for ZTE and LG in spite of the dangers to the market from political turmoil. Our economy and Europe are doing well, so I believe that corrections will be bought into. Usually when the directors at IDCC get big bonuses, announcements of new licenses follow within a few months.
That's ridiculous. Intel purchased the patents that IDCC was willing to part with.
I was thinking a fund decided to sell it's shares.
Thanks DWS- I sure hope we have a positive day on the street tomorrow to go with blow-out earnings!
Aren't IDCC earnings tomorrow? Seems they would have sent out a reminder PR with times and phone numbers for the conference call. I have even had difficulty finding the original announcement months ago.
Doesn't IDCC announce earnings this week? I can't find it anywhere.
I wonder how many lurkers there are on this board that have been invested for many years, like me, since 2000? More than half do my shares are $8 purchase price. Congrats to all longs and may we soon be geniuses. My intuition says we will see $80 in the next few months.
New 52 week high! Today IDCC definitely not trading with the market.
All chip stocks are up today because of the BRCM Avago deal.